US SB456 | 2017-2018 | 115th Congress
Status
Spectrum:
Status: Introduced on February 27 2017 - 25% progression, died in committee
Action: 2017-02-27 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 27 2017 - 25% progression, died in committee
Action: 2017-02-27 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
RACE for Children Act Research to Accelerate Cures and Equity for Children Act This bill amends the Federal Food, Drug, and Cosmetic Act to expand Food and Drug Administration (FDA) requirements for sponsors of certain drugs and biological products for adult cancer to assess the use of their medications in pediatric populations. (Currently, applications for FDA approval of new medications or new uses of medications must include pediatric assessments of safety and effectiveness for claimed indications, with exceptions.) The pediatric assessment for medications, including orphan drugs, that are used to treat cancer in adults and target a molecule germane to pediatric cancer must assess the safety and effectiveness of the medication for pediatric cancer. The bill limits waivers of pediatric assessments for medications that target a molecule germane to a pediatric cancer for which there is a need for additional treatment options. The FDA may require the sponsor of an approved medication that targets a molecule germane to pediatric cancer to complete a pediatric assessment if: (1) the medication is used for a substantial number of pediatric cancer patients, or (2) there is reason to believe the medication would have a meaningful therapeutic benefit over existing therapies for pediatric cancer patients. The FDA committee that reviews requests for pediatric studies must implement a plan to achieve earlier submission of pediatric studies. (Currently, completion of pediatric clinical studies requested by the FDA extends the patents or marketing exclusivity period for a medication by six months, with exceptions.) The FDA must act within 120 days on proposed pediatric study requests and proposed amendments to requests.
Title
RACE for Children Act Research to Accelerate Cures and Equity for Children Act
Sponsors
Sen. Michael Bennet [D-CO] | Sen. Marco Rubio [R-FL] | Sen. Chris Van Hollen [D-MD] | Sen. Cory Gardner [R-CO] |
Sen. Angus King [I-ME] |
History
Date | Chamber | Action |
---|---|---|
2017-02-27 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB1231 (Same As) 2017-03-03 - Referred to the Subcommittee on Health.
Subjects
Cancer
Child health
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Medical research
Child health
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Medical research
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/senate-bill/456/all-info |
Text | https://www.congress.gov/115/bills/s456/BILLS-115s456is.pdf |